Chugai Pharmaceutical Renovates Its Website for Actemra, Drug for the Castleman's Disease.Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, Jan 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Chugai Pharmaceutical has renovated its website for Actemra, its proprietary agent for treating the Castleman's disease Castleman's disease A heterogeneous group of idiopathic, multicentric lymphoproliferative disorders primarily of young adults Clinical Hepatosplenomegaly, lymphadenopathy Lab ↑ IL-6 in serum and tissues, anemia, hypoalbuminemia, hypergammaglobulinemia . The face-lifted website (only in Japanese Japanese (jăp'ənēz`), language of uncertain origin that is spoken by more than 125 million people, most of whom live in Japan. There are also many speakers of Japanese in the Ryukyu Islands, Korea, Taiwan, parts of the United States, and at http://www.actemra.jp/) consists of two parts: one for patients and the other for medical professionals. The company provides useful information on Actemra and the Castleman's disease for patients while supplying in-depth production information to the professionals. Through these means, the company aims to raise awareness for the Castleman's disease and promote the proper use of Actemra, the world's only agent for treating the disease. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion